Detalhe da pesquisa
1.
Minimal residual disease-driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL.
Blood
; 140(22): 2348-2357, 2022 12 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35921541
2.
Identifying and addressing unmet clinical needs on the use of zanubrutinib in chronic lymphocytic leukemia: A consensus-based position paper from an ad hoc expert panel.
Hematol Oncol
; 42(2): e3255, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-38362952
3.
Unmet clinical needs in the use of zanubrutinib in malignant lymphomas (Waldenström macroglobulinemia, marginal zone lymphoma and mantle cell lymphoma): A consensus-based position paper from an ad hoc expert panel.
Hematol Oncol
; 41(5): 795-808, 2023 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-37165730
4.
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia.
Future Oncol
; 19(5): 345-353, 2023 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-36815271
5.
Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study.
Blood
; 133(4): 299-305, 2019 01 24.
Artigo
Inglês
| MEDLINE | ID: mdl-30523119
6.
Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study.
Blood
; 134(10): 798-801, 2019 09 05.
Artigo
Inglês
| MEDLINE | ID: mdl-31292118
7.
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group.
Hematol Oncol
; 39(3): 326-335, 2021 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-33739461
8.
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases.
Eur J Haematol
; 106(4): 493-499, 2021 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-33378569
9.
Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia.
Br J Haematol
; 190(6): 901-908, 2020 09.
Artigo
Inglês
| MEDLINE | ID: mdl-32712965
10.
Targeted next-generation sequencing reveals molecular heterogeneity in non-chronic lymphocytic leukemia clonal B-cell lymphocytosis.
Hematol Oncol
; 38(5): 689-697, 2020 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-32738175
11.
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies.
Am J Hematol
; 95(12): 1473-1478, 2020 12.
Artigo
Inglês
| MEDLINE | ID: mdl-32780514
12.
A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders.
Br J Haematol
; 187(4): 441-446, 2019 11.
Artigo
Inglês
| MEDLINE | ID: mdl-31276195
13.
Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia.
Hematol Oncol
; 37(2): 117-128, 2019 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-30192023
14.
Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network.
Hematol Oncol
; 37(2): 160-167, 2019 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-30726562
15.
Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.
Am J Hematol
; 94(11): 1193-1199, 2019 11.
Artigo
Inglês
| MEDLINE | ID: mdl-31378966
16.
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.
N Engl J Med
; 373(18): 1733-47, 2015 Oct 29.
Artigo
Inglês
| MEDLINE | ID: mdl-26352686
17.
Molecular remission is an independent predictor of progression-free survival in patients with Waldenström macroglobulinemia treated with chemo-immunotherapy: Results from the FIL_BIOWM study.
Hematol Oncol
; 41(3): 574-577, 2023 08.
Artigo
Inglês
| MEDLINE | ID: mdl-36218059
18.
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study.
Am J Hematol
; 98(2): E24-E27, 2023 02.
Artigo
Inglês
| MEDLINE | ID: mdl-36349541
19.
Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report.
Blood
; 136(6): 763-766, 2020 08 06.
Artigo
Inglês
| MEDLINE | ID: mdl-32559271
20.
Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis.
Blood
; 135(4): 293-296, 2020 01 23.
Artigo
Inglês
| MEDLINE | ID: mdl-31714952